PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 495/00

A2

(11) International Publication Number: WO 00/20421

(43) International Publication Date: 13 April 2000 (13.04.00)

(21) International Application Number: PCT/EP99/07419

(22) International Filing Date: 1 October 1999 (01.10.99)

(30) Priority Data:
98203370.6 6 October 1998 (06.10.98) EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KENNIS, Ludo, Edmond, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). VAN DEN KEYBUS, Frans, Maria, Alfons [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). MERTENS, Josephus, Carolus [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).


(74) Agent: DAELEMANS, Frank; Janssen Pharmaceutica N.V., Patent Department, Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: TRICYCLIC Δ3–PIPERIDINES AS α_2–ANTAGONISTS



(I)

(57) Abstract

The present invention concerns the compounds of formula (I), the *N*–oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C_{1-6}alkanediyl; n is 1 or 2; X_1 is –O–, –S–, –S(=O)– or –S(=O)$_2$–; each R^1 is independently hydrogen, halogen, C_{1-6}alkyl, nitro, hydroxy or C_{1-4}alkyloxy; D is an optionally substituted mono, bi– or tricyclic nitrogen containing heterocycle, a 2*H*–benzopyranone, a benzamide, a benzophenone or a phenoxyphenyl having central α_2–adrenoceptor antagonist activity. It further relates to their preparation, pharmaceutical use and compositions.